1-cyclopentyl-6-{(3,4-trans)-1-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-4-methylpyrrolidin-3-yl}-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one | 1082744-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 1-cyclopentyl-6-{(3,4-trans)-1-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-4-methylpyrrolidin-3-yl}-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: trans-1-cyclopentyl-6-(1-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-4-methylpyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one；1-cyclopentyl-6-[(3S,4S)-1-[(2,5-dimethylpyrazol-3-yl)methyl]-4-methylpyrrolidin-3-yl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
• CAS: 1082744-42-0
• 化学式: C₂₁H₂₉N₇O
• 分子量: 395.508
• InChiKey: LLIYAZFYRUESNK-FZKQIMNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  80.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-cyclopentyl-6-[(3S,4S)-4-methylpyrrolidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 、 1,3-二甲基-1H-吡唑-5-甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 20.0h， 生成 1-cyclopentyl-6-{(3,4-trans)-1-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-4-methylpyrrolidin-3-yl}-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy

  摘要：

  By use of chemical enablement and prospective design, it novel series of selective, brain penetrant PDE9A inhibitors have been identified that are capable of producing in vivo elevations of brain cGMP.

  DOI：

  10.1021/jm9015334

文献信息

• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Verhoest Patrick R.

  公开号：US20090030003A1

  公开（公告）日：2009-01-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  该发明提供了式（I）的PDE9抑制化合物及其药用盐，其中R、R1、R2和R3如本文所定义。还提供了含有式I化合物的药物组合物，并将其用于治疗神经退行性和认知障碍，如阿尔茨海默病和精神分裂症。
• US7964607B2
  申请人：——

  公开号：US7964607B2

  公开（公告）日：2011-06-21
• [EN] AMINO-HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS AMINO-HÉTÉROCYCLIQUES
  申请人：PFIZER

  公开号：WO2008139293A1

  公开（公告）日：2008-11-20

  [EN] The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R₁, R₂ and R₃ are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
  [FR] L'invention porte sur des composés inhibant PDE9 de Formule (I) et sur des sels pharmaceutiquement acceptables de ceux-ci, où R, R₁, R₂ et R₃ sont tels que définis présentement. L'invention porte également sur des compositions pharmaceutiques contenant les composés de Formule I et sur les utilisations de celles-ci dans le traitement de troubles neurodégénératifs et cognitifs, tels que la maladie d'Alzheimer et la schizophrénie.
• Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy
  作者：Patrick R. Verhoest、Caroline Proulx-Lafrance、Michael Corman、Lois Chenard、Christopher J. Helal、Xinjun Hou、Robin Kleiman、Shenping Liu、Eric Marr、Frank S. Menniti、Christopher J. Schmidt、Michelle Vanase-Frawley、Anne W. Schmidt、Robert D. Williams、Frederick R. Nelson、Kari R. Fonseca、Spiros Liras

  DOI：10.1021/jm9015334

  日期：2009.12.24

  By use of chemical enablement and prospective design, it novel series of selective, brain penetrant PDE9A inhibitors have been identified that are capable of producing in vivo elevations of brain cGMP.